Tetra Bio-Pharma Inc.

About the Company

Tetra Bio-Pharma is focused on providing clinical programs aimed at bringing novel drugs and treatments to patients and their healthcare providers.

Tetra Bio-Pharma is specialized in combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

CompanyTetra Bio-Pharma Inc.
Founded2007
Head OfficeOntario, Canada
SectorHealthcare
IndustryBiotechnology
Websitehttps://tetrabiopharma.com/

 

Stock Analysis

Exchange: Frankfurt & Tradegate

Currency: Euro (€)

The Team

News & Updates

Press Release

Social Channels

Disclaimer

The information provided does not constitute an investment recommendation or a solicitation to buy or sell any securities and cannot replace a professional investment advice. Any investment in shares involves risks that can lead to a total loss of the invested capital. Any decision for subscription, purchase or sale of a particular security should be based on adequate, unbiased information, and if necessary, consultation with a professional investment advisor. CM-Equity does not provide such investment advice. As part of the investment brokerage, the institute may receive a commission of up to ten percent of the investment amount. CM-Equity could not verify the assumptions underlying to the provided information and forecasts, because they are not known. In particular CM-Equity does not guarantee that stated revenues, earnings or other projections will occur or stated targets will be reached. If the information provided forward-looking statements, in particular about the price development of markets or securities, these are considered forecasts whose occurrence is unknown. CM-Equity AG may receive a consulting fee from the company. The CM-Equity AG and persons or companies affiliated with it may hold shares of the listed companies or buy positions in the daily business and sell, whereby a potential conflict of interest arises. CM-Equity has taken certain precautions to reduce such conflict. In this context a detailed work instruction for such transactions has been released. However, a conflict between personal interests and the interests of investors cannot be excluded.